



September 10, 2021

Name of Company: Meiji Holdings Co., Ltd.
Name of Representative: Kazuo Kawamura, CEO, President and Representative Director
Code Number: 2269, 1st Section, Tokyo Stock Exchange

Notice concerning Recording Extraordinary Profit and Revisions to Financial Forecasts for the Fiscal Year Ending March 31, 2022

Meiji Holdings Co., Ltd. (the “Company”) today announces that we revised our earnings forecasts for the fiscal year ending March 31, 2022 (FY2021), announced on May 18, 2021, as described below.

1. Details of Extraordinary Profit

As disclosed on August 12, 2021, in the “Consolidated Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2022,” our subsidiary Meiji Seika Pharma Co., Ltd. (hereinafter, Meiji Seika Pharma) plans to transfer all its stock holdings in the equity method affiliate DM Bio Limited (hereinafter, DM Bio) to the Dong-A Socio Group in September 2021. Due to this transfer, the Company is planning to record gain on sales of investment securities of approximately JPY 2,500 million (estimated) as extraordinary profit in the second quarter of FY2021.

As announced on September 10, 2021, Meiji Seika Pharma plans to transfer its agricultural chemicals business to Mitsui Chemicals Agro, Inc. in January 2022. Due to this transfer the Company is planning to record extraordinary profit of approximately JPY 37,000 million (estimated) in the fourth quarter of FY2021.

2. Revised Forecasts of Consolidated Financial Results for the First Six Months of the Fiscal Year Ending March 31, 2022 (April 1, 2021 to September 30, 2021)

	Net sales	Operating profit	Ordinary profit	Profit attributable to owners of parent	Profit per share
	millions of yen	millions of yen	millions of yen	millions of yen	yen
Previous forecasts (A)	505,000	51,000	52,000	31,000	213.65
Revised forecasts (B)	505,000	51,000	52,000	34,000	234.32
Change (B-A)	—	—	—	3,000	
Percentage of change	—	—	—	9.7	
(Reference) Results for the first six months of the fiscal year ended March 31, 2021	584,976	50,401	50,655	28,733	198.05

(Note) The Accounting Standard for Revenue Recognition (ASBJ Statement No. 29, March 31, 2020) is applied from the beginning of the first quarter of FY2021.

3. Revised Forecasts of Consolidated Financial Results for the Fiscal Year Ending March 31, 2022 (April 1, 2021 to March 31, 2022)

	Net sales	Operating profit	Ordinary profit	Profit attributable to owners of parent	Profit per share
	millions of yen	millions of yen	millions of yen	millions of yen	yen
Previous forecasts (A)	1,024,000	107,500	109,000	67,000	461.76
Revised forecasts (B)	1,019,000	106,000	107,500	95,000	654.73
Change (B-A)	-5,000	-1,500	-1,500	28,000	
Percentage of change	-0.5	-1.4	-1.4	41.8	
(Reference) Results for the fiscal year ended March 31, 2021	1,191,765	106,061	110,176	65,655	452.52

(Note) The Accounting Standard for Revenue Recognition (ASBJ Statement No. 29, March 31, 2020) is applied from the beginning of the first quarter of FY2021.

4. Reasons for Revisions

We revised the consolidated results forecast for FY2021 due to the following expected impact.

Forecast for the first six months of FY2021: We considered the impact from recording extraordinary profit due to the transfer all its stock holdings in DM Bio.

Forecast for FY2021: We considered the decrease in sales and profits and the impact from recording extraordinary profit due to the transfer the agricultural chemicals business in addition to the transfer of DM Bio.

There are no changes to the consolidated sales and profits forecasts for all the existing business excluding agricultural chemicals business for FY2021 announced on May 18, 2021.

5. Dividend Forecast

This revision of the consolidated results forecast for FY2021 does not impact the Company's dividend forecast.

* Financial forecasts indicated in these materials are based on information currently available to the company and certain assumptions deemed to be reasonable. Actual financial results may change due to various factors.

#####